Nearly 3.8 million U.S. women are living after breast cancer in 2024, but the path beyond diagnosis looks uneven when you compare outcomes and day to day side effects. One-third of survivors report fair or poor health and fatigue, pain, and nerve symptoms can linger, even as treatments improve survival. This post brings together the most recent U.S. snapshots on recurrence, survival, and quality of life so you can see what “survivorship” means across stages and years.
Key Takeaways
- In the U.S., stage at diagnosis distribution for breast cancer includes 38% localized, 34% regional, and 22% distant (2012–2018 snapshot)
- Breast cancer is the most common cancer among U.S. women except non-melanoma skin cancer
- In 2024, the U.S. had about 3.8 million women who were breast cancer survivors
- 2.9% of U.S. women are living with breast cancer in 2022 (prevalence proportion)
- About 1 in 3 (33%) breast cancer survivors in the U.S. report fair or poor health status (2019 survey estimate)
- 5-year breast cancer-specific survival was 26.0% for distant disease in the cohort
- In the U.S., about 1 in 8 women diagnosed with breast cancer will have a recurrence within 10 years (estimate for hormone receptor-positive disease varies by treatment)
- In ER-positive breast cancer treated with endocrine therapy, late recurrence risk persists beyond 5 years (hazard depends on risk group)
- About 1 in 3 breast cancer survivors experience sexual dysfunction (reviewed estimates)—a major quality-of-life outcome
- Nearly 50% of breast cancer survivors report fatigue symptoms (meta-analytic estimates)—one of the most persistent complaints
- Depression affects about 25% of cancer survivors in general (meta-analysis)—including breast cancer populations
- About 35% of breast cancer survivors report cognitive concerns (reviewed prevalence)—often described as “chemo brain”
- ~30% of women on endocrine therapy develop arthralgia symptoms (clinical review evidence)—a common long-term treatment side effect
- 20% of women treated with aromatase inhibitors develop osteopenia and 10% develop osteoporosis by follow-up (reviewed estimates)—bone health impact
- 12% of women with prior breast cancer report a second breast cancer (new primary) within 10 years (population-level estimate from cohort evidence)
In the US, most breast cancers are caught early, yet survivors face long term physical and mental health challenges.
Related reading
01 · Category
Survivorship Incidence2 stats
01
In the U.S., stage at diagnosis distribution for breast cancer includes 38% localized, 34% regional, and 22% distant (2012–2018 snapshot)
02
Breast cancer is the most common cancer among U.S. women except non-melanoma skin cancer
Interpretation
Survivorship Incidence Interpretation
From a survivorship incidence angle, most U.S. breast cancer cases are diagnosed earlier with 38% localized and 34% regional compared with 22% distant, showing that a large share of survivors start out with less advanced disease than the most serious distant stage.
02 · Category
Survivorship Prevalence3 stats
01
In 2024, the U.S. had about 3.8 million women who were breast cancer survivors
02
2.9% of U.S. women are living with breast cancer in 2022 (prevalence proportion)
03
About 1 in 3 (33%) breast cancer survivors in the U.S. report fair or poor health status (2019 survey estimate)
Interpretation
Survivorship Prevalence Interpretation
Within the survivorship prevalence picture, the U.S. had about 3.8 million breast cancer survivors in 2024, but the reality of living with the condition remains notable with 2.9% of women affected in 2022 and as many as 33% reporting fair or poor health in 2019.
03 · Category
Survivorship Outcomes3 stats
01
5-year breast cancer-specific survival was 26.0% for distant disease in the cohort
02
In the U.S., about 1 in 8 women diagnosed with breast cancer will have a recurrence within 10 years (estimate for hormone receptor-positive disease varies by treatment)
03
In ER-positive breast cancer treated with endocrine therapy, late recurrence risk persists beyond 5 years (hazard depends on risk group)
Interpretation
Survivorship Outcomes Interpretation
In survivorship outcomes, the 5-year breast cancer-specific survival drops to 26.0% for distant disease while U.S. estimates show that about 1 in 8 women experience recurrence within 10 years, and for ER-positive patients on endocrine therapy the risk still persists beyond 5 years.
04 · Category
Quality Of Life5 stats
01
About 1 in 3 breast cancer survivors experience sexual dysfunction (reviewed estimates)—a major quality-of-life outcome
02
Nearly 50% of breast cancer survivors report fatigue symptoms (meta-analytic estimates)—one of the most persistent complaints
03
Depression affects about 25% of cancer survivors in general (meta-analysis)—including breast cancer populations
04
An estimated 10–30% of cancer survivors experience anxiety symptoms (systematic review)—mental health burden after treatment
05
8.4% of breast cancer survivors reported pain interfering with daily activities (U.S. survey estimate)
Interpretation
Quality Of Life Interpretation
Quality of life after breast cancer is heavily impacted by persistent, treatment lasting symptoms, with nearly 50% reporting fatigue and about 1 in 3 experiencing sexual dysfunction, while mental health concerns also remain common at roughly 25% for depression and 10% to 30% for anxiety.
05 · Category
Long Term Effects4 stats
01
About 35% of breast cancer survivors report cognitive concerns (reviewed prevalence)—often described as “chemo brain”
02
~30% of women on endocrine therapy develop arthralgia symptoms (clinical review evidence)—a common long-term treatment side effect
03
20% of women treated with aromatase inhibitors develop osteopenia and 10% develop osteoporosis by follow-up (reviewed estimates)—bone health impact
04
Cardiovascular disease accounts for a substantial fraction of excess mortality in cancer survivors—about 40% of deaths after cancer are attributed to cardiovascular causes in observational evidence (cancer survivor analyses)
Interpretation
Long Term Effects Interpretation
In the long term effects category, breast cancer survivorship often comes with persistent health burdens, including about 35% reporting cognitive concerns, roughly 30% experiencing endocrine therapy related joint pain, and significant long term bone and heart risks with osteopenia in 20% and osteoporosis in 10% and cardiovascular causes accounting for about 40% of deaths after cancer.
06 · Category
Survival Outcomes1 stats
01
12% of women with prior breast cancer report a second breast cancer (new primary) within 10 years (population-level estimate from cohort evidence)
Interpretation
Survival Outcomes Interpretation
From a survival outcomes perspective, about 12% of women who have previously had breast cancer develop a second new primary breast cancer within 10 years, underscoring that long term recurrence risk remains a key concern for survivors.
More related reading
07 · Category
Survivorship Burden2 stats
01
A 2017–2018 U.S. survey found 51% of cancer survivors reported receiving information about follow-up care (including breast cancer survivors)—supporting care transitions
02
In a U.S. cohort study, 38% of breast cancer survivors report at least one treatment-related comorbidity (observational clinical data)—increasing post-treatment complexity
Interpretation
Survivorship Burden Interpretation
Survivorship burden is evident because only 51% of cancer survivors, including breast cancer survivors, reported receiving follow-up care information while 38% of breast cancer survivors reported at least one treatment-related comorbidity, showing that many people must manage complex ongoing needs after treatment.
08 · Category
Incidence & Mortality1 stats
01
Breast cancer screening has a high use rate: 72% of U.S. women age 50–74 reported ever having a mammogram within the past 2 years (2022 BRFSS)—screening utilization metric
Interpretation
Incidence & Mortality Interpretation
Under the Incidence and Mortality angle, the fact that 72% of U.S. women ages 50 to 74 reported having a mammogram within the past 2 years in 2022 suggests that widespread screening is helping support earlier detection efforts.
09 · Category
Treatment & Care8 stats
01
In 2021, the most common initial treatment among U.S. patients diagnosed with early-stage breast cancer included breast-conserving surgery plus radiation in a majority of cases (national claims/registry reporting—SEER-linked study evidence)
02
Adjuvant aromatase inhibitor therapy reduces breast cancer recurrence risk by about 40% relative to no endocrine therapy in hormone receptor-positive settings (meta-analysis evidence)
03
Tamoxifen for 5 years reduces the risk of breast cancer recurrence by roughly 30% in ER-positive disease (Early Breast Cancer Trialists’ meta-analysis)
04
Trastuzumab-based therapy improved 10-year survival in HER2-positive breast cancer by about 6–7 percentage points in major trial results (HERA/Aphrodite long-term follow-up reporting)
05
Radiation therapy after lumpectomy reduces local recurrence risk by about 70% versus lumpectomy alone (randomized trial synthesis evidence)
06
Surgical sentinel lymph node biopsy decreases lymphedema risk compared with axillary lymph node dissection—rates often reduced by about 50% in trial comparisons (systematic review evidence)
07
Adherence to endocrine therapy in the U.S. is low: only about 50% of women remain persistent at 12 months (claims-based adherence studies)
08
Majority of U.S. breast cancer survivors use multiple healthcare services annually: 1 in 5 survivors had 10+ visits to outpatient facilities in a year (U.S. claims evidence)
Interpretation
Treatment & Care Interpretation
Treatment for breast cancer is highly multimodal, with most early-stage U.S. patients receiving breast-conserving surgery plus radiation in 2021, while the biggest ongoing care challenge is adherence, since only about half of women stay on endocrine therapy at 12 months despite its recurrence-reducing benefits of roughly 30% to 40%.
10 · Category
Cost Analysis3 stats
01
Total annual economic burden of breast cancer in the U.S. was $19.9 billion in 2013 (direct + indirect cost estimate in published analysis)
02
U.S. cancer survivors have higher healthcare costs than people without cancer: average incremental annual costs can be several thousand dollars (U.S. administrative data studies; magnitude varies by time since diagnosis)
03
Out-of-pocket spending is common among cancer survivors: about 1 in 4 cancer survivors report any out-of-pocket medical expenses in a given period (U.S. survey evidence)
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, breast cancer added an estimated $19.9 billion to the U.S. economy in 2013 and survivors often face higher healthcare costs and out-of-pocket burdens, with about 1 in 4 reporting medical expenses, showing how financial strain extends well beyond treatment alone.
11 · Category
Health Care Utilization2 stats
01
35.1% of breast cancer survivors had at least one emergency department visit within 12 months (claims analysis)
02
4.6% of breast cancer survivors reported being hospitalized in the past 12 months (U.S. survey estimate)
Interpretation
Health Care Utilization Interpretation
Under health care utilization, 35.1% of breast cancer survivors had at least one emergency department visit in the prior 12 months, while 4.6% reported being hospitalized, suggesting that urgent care use is much more common than inpatient stays.
12 · Category
Long Term Treatment Effects6 stats
01
2.1% of women with breast cancer had lymphedema prevalence reported in a U.S. administrative data study (rate per 100 women)
02
17% of breast cancer survivors reported upper-extremity swelling/lymphedema symptoms (survey-based prevalence estimate)
03
14% of breast cancer survivors have peripheral neuropathy symptoms (pooled estimate from systematic review)
04
10% of breast cancer survivors report chemotherapy-induced neuropathy persisting beyond 1 year (systematic review estimate)
05
19% of breast cancer survivors report arm/shoulder dysfunction (patient-reported outcomes estimate)
06
8% of breast cancer survivors reported treatment-related cognitive impairment (survey estimate)
Interpretation
Long Term Treatment Effects Interpretation
Long term treatment effects remain common for breast cancer survivors, with one in five reporting arm or shoulder dysfunction and around one in six reporting upper extremity swelling or cognitive impairment, while neuropathy affects roughly 14% overall and 10% experience chemotherapy induced neuropathy beyond a year.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Breast Cancer Survivor Statistics. Gitnux. https://gitnux.org/breast-cancer-survivor-statistics
MLA
Min-ji Park. "Breast Cancer Survivor Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-survivor-statistics.
Chicago
Min-ji Park. 2026. "Breast Cancer Survivor Statistics." Gitnux. https://gitnux.org/breast-cancer-survivor-statistics.
Sources & references
40 datasets cited across this report · attribution is report-level
+22 additional datasets cited (not shown individually)